메뉴 건너뛰기
Japanese Journal of Antibiotics
Volumn 65, Issue 4, 2012, Pages 263-269
Clinical investigation of arbekacin sulfate based on Cmax/MIC
Author keywords

[No Author keywords available]
Indexed keywords

ANTIINFECTIVE AGENT; ARBEKACIN SULFATE; HABEKACIN; UNCLASSIFIED DRUG;
EID: 84866421309     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (2)
References (22)
  • 1
    • 0031952586 scopus 로고    scopus 로고
    • Parmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    • CRAIG, W. A.: Parmacokinetic/pharmacodynamic parameters : rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26: 1-12, 1998
    • (1998) Clin. Infect. Dis. , vol.26 , pp. 1-12
    • Craig, W.A.1
  • 2
    • 0024441288 scopus 로고
    • Determinants of efficacy and toxicity of aminoglycosides
    • MATTIE, H.; W. A. CRAIG & J. C. PECHERE: Determinants of efficacy and toxicity of aminoglycosides. J. Antimicrob. Chemother. 24: 281-293, 1989
    • (1989) J. Antimicrob. Chemother. , vol.24 , pp. 281-293
    • Mattie, H.1    Craig, W.A.2    Pechere, J.C.3
  • 3
    • 3142775201 scopus 로고    scopus 로고
    • The role of pharmacodynamics in effective treatment of community-acquired pathogens
    • CRAIG, W. A.: The role of pharmacodynamics in effective treatment of community-acquired pathogens. Adv. Stud. Med. 2: 126-134, 2002
    • (2002) Adv. Stud. Med. , vol.2 , pp. 126-134
    • Craig, W.A.1
  • 4
    • 84886949943 scopus 로고    scopus 로고
    • Japanese source
  • 5
    • 84886949135 scopus 로고    scopus 로고
    • Japanese source
  • 6
    • 0023119430 scopus 로고
    • Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
    • MOORE, R. D.; P. S. LIETMAN & C. R. SMITH: Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155: 93-99, 1987
    • (1987) J. Infect. Dis. , vol.155 , pp. 93-99
    • Moore, R.D.1    Lietman, P.S.2    Smith, C.R.3
  • 7
    • 0027518301 scopus 로고
    • Once versus thrice daily gentamicin in patients with serious infections
    • PRINS, J. M.; H. R. BULLER, E. J. KUIJPER, et al.: Once versus thrice daily gentamicin in patients with serious infections. Lancet 341: 335-339, 1993
    • (1993) Lancet , vol.341 , pp. 335-339
    • Prins, J.M.1    Buller, H.R.2    Kuijper, E.J.3
  • 8
    • 0029879960 scopus 로고    scopus 로고
    • Effectiveness and safety of once-daily aminoglycosides: A meta-analysis
    • FERRIOLS-LISART, R. & M. ALOS-ALMINANA: Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am. J. Health Syst. Pharm. 53: 1141-1150, 1996
    • (1996) Am. J. Health Syst. Pharm. , vol.53 , pp. 1141-1150
    • Ferriols-Lisart, R.1    Alos-Alminana, M.2
  • 9
    • 0029803233 scopus 로고    scopus 로고
    • Mega-analysis of meta-analysis: An examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials
    • FREEMAN, C. D. & A. H. STRAYER: Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacother. 16: 1093-1102, 1996
    • (1996) Pharmacother. , vol.16 , pp. 1093-1102
    • Freeman, C.D.1    Strayer, A.H.2
  • 10
    • 0030893852 scopus 로고    scopus 로고
    • A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides
    • ALI, M. Z. & M. B. GOETZ: A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin. Infect. Dis. 24: 796-809, 1997
    • (1997) Clin. Infect. Dis. , vol.24 , pp. 796-809
    • Ali, M.Z.1    Goetz, M.B.2
  • 11
    • 84886949505 scopus 로고    scopus 로고
    • Japanese source
  • 12
    • 84886948519 scopus 로고    scopus 로고
    • Japanese source
  • 13
    • 84886949619 scopus 로고    scopus 로고
    • Japanese source
  • 14
    • 84886948334 scopus 로고    scopus 로고
    • Japanese source
  • 15
    • 84886949409 scopus 로고    scopus 로고
    • Japanese source
  • 16
    • 84886951870 scopus 로고    scopus 로고
    • Japanese source
  • 17
    • 84886949060 scopus 로고    scopus 로고
    • Japanese source
  • 18
    • 33750593916 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus
    • SATO, R.; Y. TANIGAWARA, M. KAKU, N. AIKAWA, et al.: Pharmacokinetic- pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 3763-3769, 2006
    • (2006) Antimicrob. Agents Chemother. , vol.50 , pp. 3763-3769
    • Sato, R.1    Tanigawara, Y.2    Kaku, M.3    Aikawa, N.4
  • 19
    • 84886951378 scopus 로고    scopus 로고
    • Japanese source
  • 20
    • 84863326417 scopus 로고    scopus 로고
    • The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection
    • YAMAMOTO, Y.; K. IZUMIKAWA, K. HASHIGUCHI, et al.: The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection. J. Infect. Chemother. 18: 241-246, 2012
    • (2012) J. Infect. Chemother. , vol.18 , pp. 241-246
    • Yamamoto, Y.1    Izumikawa, K.2    Hashiguchi, K.3
  • 21
    • 0032701245 scopus 로고    scopus 로고
    • Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside
    • MURRY, K. R.; P. S. MCKINNON, B. MITRZYK, et al.: Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacother. 19: 1252-1260, 1999
    • (1999) Pharmacother. , vol.19 , pp. 1252-1260
    • Murry, K.R.1    Mckinnon, P.S.2    Mitrzyk, B.3
  • 22
    • 84886949625 scopus 로고    scopus 로고
    • Japanese source

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.